Richard Barry
Richard Barry's purchase track record
How the stock did after each of Richard Barry's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 9/28/2026 | FLNA | $356K | pending | pending | — |
| 11/19/2025 | FLNA | $616K | -22.6% | -54.5% | +11.9% |
| 9/18/2025 | FLNA | $551K | +24.4% | -20.1% | -0.4% |
| 11/3/2023 | SRPT | $3.94M | +55.5% | +71.3% | +17.6% |
| 8/21/2023 | FLNA | $308K | +36.2% | +33.9% | +13.1% |
| 3/6/2023 | FLNA | $2.29M | -13.0% | -20.1% | +11.1% |
| 8/23/2022 | FLNA | $860K | +30.0% | -0.4% | -3.2% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
Sarepta settles patent dispute with REGENXBIO for $39M. Sarepta Therapeutics has resolved all ongoing patent litigation with REGENXBIO through a $39 million settlement. The agreement includes a clause where REGENXBIO agrees not to sue Sarepta over existing Elevidys or AAVrh74-based capsids. This development removes a significant legal uncertainty surrounding the company's key product, allowing Sarepta to focus on presenting new neuromuscular data at an upcoming scientific meeting.
Transaction History
| FLNA | ▲ Buy | Open Market | 100,000 | $92K | 9/30/2026 | View on chart |
| FLNA | ▲ Buy | Open Market | 206,813 | $186K | 9/29/2026 | View on chart |
| FLNA | ▲ Buy | Open Market | 93,091 | $78K | 9/28/2026 | View on chart |
| SRPT | ▲ Buy | Grant | 16,875 | — | 6/4/2026 | View on chart |
| FLNA | ▲ Buy | Open Market | 150,000 | $414K | 11/20/2025 | View on chart |
| FLNA | ▲ Buy | Open Market | 73,385 | $202K | 11/19/2025 | View on chart |
| FLNA | ▲ Buy | Open Market | 7,172 | $16K | 9/22/2025 | View on chart |
| FLNA | ▲ Buy | Open Market | 400 | $900 | 9/19/2025 | View on chart |
| FLNA | ▲ Buy | Open Market | 46,908 | $107K | 9/19/2025 | View on chart |
| FLNA | ▲ Buy | Open Market | 5,400 | $12K | 9/18/2025 | View on chart |
| FLNA | ▲ Buy | Open Market | 185,233 | $415K | 9/18/2025 | View on chart |
| SRPT | ▲ Buy | Option Exercise | 12,350 | $403K | 5/16/2025 | View on chart |
| SRPT | ▲ Buy | Option Exercise | 9,746 | $245K | 5/13/2025 | View on chart |
| SRPT | ▲ Buy | Option Exercise | 10,500 | $144K | 5/13/2025 | View on chart |
| SRPT | ▲ Buy | Grant | 2,383 | $0 | 3/10/2025 | View on chart |
| FLNA | ▲ Buy | Option Exercise | 176,085 | $3.9M | 4/23/2024 | View on chart |
| SRPT | ▲ Buy | Grant | 1,846 | $0 | 3/1/2024 | View on chart |
| SRPT | ▲ Buy | Open Market | 40,000 | $3.2M | 11/3/2023 | View on chart |
| SRPT | ▲ Buy | Open Market | 10,000 | $788K | 11/3/2023 | View on chart |
| FLNA | ▲ Buy | Open Market | 16,571 | $276K | 8/22/2023 | View on chart |
| FLNA | ▲ Buy | Open Market | 1,906 | $32K | 8/21/2023 | View on chart |
| FLNA | ▲ Buy | Open Market | 77,276 | $2.0M | 3/7/2023 | View on chart |
| SRPT | ▲ Buy | Grant | 1,523 | $0 | 3/6/2023 | View on chart |
| FLNA | ▲ Buy | Open Market | 11,565 | $302K | 3/6/2023 | View on chart |
| FLNA | ▲ Buy | Open Market | 36,159 | $860K | 8/23/2022 | View on chart |
| SRPT | ▲ Buy | Grant | 2,953 | $0 | 3/7/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
FLNA sees unusual volume and after-hours movement
Filana Therapeutics (FLNA) appeared on multiple lists for unusual trading volume and price gaps during recent sessions. The stock also showed notable movement in after-hours trading, drawing attention from market scanners. These technical signals suggest increased investor interest or reaction to recent developments, though no specific corporate news was provided in the data.
FLNA sees unusual volume and after-hours movement. Filana Therapeutics (FLNA) appeared on multiple lists for unusual trading volume and price gaps during recent sessions. The stock also showed notable movement in after-hours trading, drawing attention from market scanners. These technical signals suggest increased investor interest or reaction to recent developments, though no specific corporate news was provided in the data.